# Forest Laboratories

Organization · id `cardio:org-forest-laboratories` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Forest+Laboratories>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 7 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Forest Laboratories
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Nebivolol in Patients With Systolic Stage 2 Hypertension (`cardio:ct-nct01057251`)
- Sponsors: Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone (`cardio:ct-nct01089790`)
- Sponsors: Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (`cardio:ct-nct01313572`)
- Sponsors: Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension (`cardio:ct-nct01415505`)
- Sponsors: Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) (`cardio:ct-nct01415531`)
- Sponsors: Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) (`cardio:ct-nct01464476`)
- Sponsors: Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension (`cardio:ct-nct01508026`)

## Provenance

Content hash: 5e61907fb24c09697a6af30f8e67cc02693233ad25eac8367da565fbad4a644d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
